Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Eli Lil­ly is once again tap­ping in­to Verve Ther­a­peu­tics, which is de­vel­op­ing one-time treat­ments in the car­dio­vas­cu­lar dis­ease space, as the phar­ma gi­ant con­tin­ues to beef up its re­search in­to ge­net­ic med­i­cines.

This time, Lil­ly is bet­ting on Verve’s pipeline by buy­ing out Beam Ther­a­peu­tics’ opt-in rights to co-de­vel­op and co-com­mer­cial­ize Verve’s base edit­ing treat­ments, the com­pa­nies said Tues­day morn­ing. Ear­li­er this sum­mer, the Big Phar­ma paid $60 mil­lion up­front to Verve for a pre­clin­i­cal-stage pro­gram tar­get­ing lipopro­tein(a), or Lp(a).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER